New agents in the treatment of acute lymphocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 771-790

  Thomas, Deborah A ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphocytic leukaemia; Drug resistance; Novel agents

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; ASPARAGINASE; BORTEZOMIB; BRYOSTATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN; FLAVOPIRIDOL; IMATINIB; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NEW DRUG; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TEZACITABINE; TRIMETREXATE; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; ANNAMYCIN; CLOFARABINE; FC RECEPTOR; FLUDARABINE; GUANINE ARABINOSIDE; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; NELARABINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOFIBRINOGENEMIA; LONG TERM CARE; MULTIMODALITY CANCER THERAPY; MYALGIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME; AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INHIBITION; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; RASH; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VOMITING;

EID: 0036955496     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2003.0234     Document Type: Review

References (113)

1. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematology and Oncology Clinics of North America 7: 1993; 139-160.
2. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995; 85: 2025-2037.
3. Kantarjian HM, O'Brien S, Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology 2000; 18: 547-561.
4. Hoelzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
5. Thomas DA, Cortes J, O'Brien S et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. Journal of Clinical Oncology 1999: 17: 2461-2470.
6. Faderl S, Kantarjian HM, Thomas DA et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma 2000; 36: 263-273.
7. Marie JP. Drug resistance in hematologic malignancies. Current Opinion in Oncology 2001; 13: 463-469.
8. Styczynski J & Wysocki M. In vitro drug resistance profiles of adult acute lymphoblastic leukemia: possible explanation for difference in outcome to similar therapeutic regimens. Leukemia and Lymphoma 2002; 43: 301-307.
9. Woo MH, Hak LJ, Storm MC et al. Anti-asparaginase antibodies following E coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533.
10. Albertsen BK, Schroder H, Jakobsen P et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Medical and Pediatric Oncology 2002; 38: 310-316.
11. Keating MJ, Holmes R, Lerner S & Ho DH. L-asparaginase and PEG asparaginase - past, present, and future. Leukemia and Lymphoma 1993; 10: 153-157.
12. Asselin BL. The three asparaginases Comparative pharmacology and optimal use in childhood leukemia. Advances in Experimental Medicine and Biology 1999; 457: 621-629.
13. Abshire TC, Pollock BH, Billett AL et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000; 96: 1709-1715.
14. Duval M, Suciu S, Ferster A et al. Comparison of Escherichia coli asparaginase with Erwinia asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-2739.
15. Nagura E, Kimura K, Yamada K et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 1994; 33: 359-365.
16. Avramis VI, Sencer S, Periclou AP et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986-1994.
17. Aguayo A, Cortes J, Thomas D et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999; 86: 1203-1209.
18. Muller HJ, Beier R, da Palma JC et al. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemotherapy and Pharmacology 2002; 49: 149-154.
19. Krishna R, Webb MS, St Onge G & Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. Journal of Pharmacology and Experimental Therapeutics 2001; 298: 1206-1212.
20. Sarris AH, Hagemeister F, Romaguera J et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Annals of Oncology 2000; 11: 69-72.
21. Thomas DA, Sarris A, O'Brien S et al. Phase II study of liposomal vincristine (LipoV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL). Blood 1999; 94: 238b. abstract 4269.
22. Cortes J, O'Brien S, Estey E et al. Phase I study of liposomal daunorubicin in patients with acute leukemia. Investigational New Drugs 1999; 17: 81-87.
23. Cortes J, Estey E, O'Brien S et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001; 92: 7-14.
24. Koller C, Cortes J, O'Brien S et al. A pilot study of dose-intensive anthracyclines for acute lymphoblastic leukemia (ALL) using liposomal daunorubicin (LD) with hyperfractionated cyclophosphamide (CTX), vincristine (VCR), and prednisone (PDN) (Hyper-CVXD). Proceedings of the American Society of Clinical Oncology 1998; 17: 28a. abstract 110.
25. Todeschini G, Meneghini V, Pizzolo G et al. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994; 8: 376-381.
26. Todeschini G, Tecchio C, Meneghini V et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998: 12; 144-149.
27. Thomas DA, Cortes J, Giles FJ et al. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL). Blood 2001; 98: 590a. abstract 2474.
28. Consoli U, Priebe W, Ling YH et al. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996; 88: 633-644.
29. Zou Y, Priebe W, Stephens LC & Perez-Soler R. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clinical Cancer Research 1: 1995; 1369-1374.
30. Andreeff M, Giles R, Sanchez-Williams G et al. Phase I study of annamycin: a novel MDR-I independent anthracycline in relapsed/refractory AML. Blood 1999; 94: 226b. abstract 4212.
31. Gorlick R, Cole P, Banerjee D et al. Mechanisms of methotrexate resistance in acute leukemia Decreased transport and polyglutamylation. Advances in Experimental Medicine and Biology 1999; 457: 543-550.
32. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology (Huntington) 1993; 7: 23-28.
33. Goasguen JE, Dossot JM, Fardel O et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-2398.
34. Whitehead VM, Rosenblatt DS, Vuchich MJ et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990; 76: 44-49.
35. Galpin AJ, Schuetz JD, Masson E et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Molecular Pharmacology 1997; 52: 155-163.
36. Synold TW, Relling MV, Boyett JM et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. Journal of Clinical Investigation 1994; 94: 1996-2001.
37. Kheradpour A, Berman E, Goker E et al. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Cancer Investigation 1995; 13: 36-40.
38. Cortes J, Plunkett W, O'Brien S et al. Phase I trial of trimetrexate (TMTX) in acute leukemias. Proceedings of the American Society of Clinical Oncology 1999; 18: 22a. abstract 80.
39. Sarris AH, Phan A, Duvic M et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. Journal of Clinical Oncology 2002; 20: 2876-2880.
40. Gandhi V, Plunkett W, Rodriguez CO Jr. et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. Journal of Clinical Oncology 1998; 16: 3607-3615.
41. O'Brien S, Thomas D, Kantarjian H et al. Compound 506 has activity in mature lymphoid leukemia. Blood 1998; 92: 490a. abstract 2022.
42. Kisor DF, Plunkett W, Kurtzberg J et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. Journal of Clinical Oncology 2000; 18: 995-1003.
43. Kurtzberg J, Ernst TJ, Keating MJ et al. A phase I study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-puine (nelarabine) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies. Blood 1999; 94: 699a. abstract 2794.
44. Gandhi V, Plunkett W, Weller S et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Journal of Clinical Oncology 2001; 19: 2142-2152.
45. Banti S, Miller PJ, Parker CD et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs-host disease: the role of dGTP in antiproliferative action of BCX-1777. International Immunopharmacology 2002; 2: 913-923.
46. Yamauchi T, Nowak BJ, Keating MJ & Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clinical Cancer Research 2001; 7: 3580-3589.
47. Kantarjian HM, Gandhi VV, O'Brien S et al. Phase I and pharmacology study of clofarabine (2-Cl-2′-F-deoxy-9-D-arabino-furanosyladenine) in solid and hematologic cancers. Blood 2001; 98: 214b.
48. Jeha S, Gandhi V, Chan KW et al. Phase I study of clofarabine (Clofarex™) in pediatric leukemia. Blood 2002; 100: 86a. abstract 315.
49. Cortes JE, Gandhi V, Plunkett W et al. Clofarabine [2-chloro-9-(2-deoxy-2-fluoro- b-D-arabinofuranosyl) adenine is active for patients with refractory or relapsed acute leukemias, myelodysplastic syndromes (MDS) and chronic myeloid leukemia in blast phase (CML-BP). Blood 2002; 100: 197a. abstract 739.
50. Piepmeier JM, Rabidou N, Schold SC et al. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL 101,731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Research 1996; 56: 359-361.
51. Zhou Y, Achanta G, Pelicano H et al. Action of (E)-2′-deoxy-2′-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Molecular Pharmacology 2002; 61: 222-229.
52. Woessner RD, Loudy DE, Wallace CD et al. Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2′-deoxy-2′-(flouromethylene) cytidine (MDL 101,731). Oncologic Research 1997; 9: 543-552.
53. Faderl S, Garcia-Manero G, Thomas DA et al. Phase I study of Tezacitabine (FMdC) in patients with relapsed and refractory hematologic malignancies. Blood 2001; 98: 595a. abstract 2493.
54. Issa JP, Baylin SB & Herman JG. DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 1997; 11: S7-S11.
55. Pinto A & Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7: 51-60.
56. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Journal of Clinical Oncology 2000; 18: 956-962.
57. Willemze R, Archimbaud E & Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993; 7: 49-50
58. Schwartsmann G, Fernandes MS, Schaan MD et al. Decitabine (5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997; 11: S28-S31.
59. Garcia-Manero G, Daniel J, Smith TL et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research 2002; 8: 2217-2224.
60. Garcia-Manero G, Bueso-Ramos C, Daniel J et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clinical Cancer Research 2002; 8: 1897-1903.
61. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 2001; 19: 3852-3860.
62. Akao Y, Mizoguchi H, Kojima S et al. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases; and down-regulation of Bcl-2 protein. British Journal of Haematology 1998; 102: 1055-1060.
63. Bazarbachi A, El-Sabban ME, Nasr R et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278-283.
64. Puccetti E, Guller S, Orleth A et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Research 2000; 60: 3409-3413.
65. 3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001; 15: 772-778.
66. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 1999; 59: 2615-2622.
67. Richardson PG, Berenson J, Irwin D et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001; 98: 774a. abstract 3223.
68. Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology 2000; 18: 1812-1823.
69. Jones RJ, Sharkis SJ, Miller CB et al. Bryostatin I, a unique biological response modifier: antileukemic activity in vitro. Blood 1990; 75: 1319-1323.
70. Varterasian ML, Mohammad RM, Eilender DS et al. Phase I study of bryostatin I in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Journal of Clinical Oncology 1998; 16: 56-62.
71. Varterasian ML, Pemberton PA, Hulburd K et al. Phase II study of bryostatin I in patients with relapsed multiple myeloma. Investigational New Drugs 2001; 19: 245-247.
72. Varterasian ML, Mohammad RM, Shurafa MS et al. Phase II trial of bryostatin I in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clinical Cancer Research 2000; 6: 825-828.
73. Wall NR, Mohammad RM, Nabha SM et al. Modulation of clAP-I by novel antitubulin agents when combined with bryostatin I results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Biochemical and Biophysical Research Communications 1999; 266: 76-80.
74. Wall NR, Mohammad RM & Al-Katib AM. Bax:Bcl-2 ratio modulation by bryostatin I and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Leukemia Research 1999; 23: 881-888.
75. Wall NR, Mohammad RM, Reddy KB et al. Bryostatin I induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. International Journal of Molecular Medicine 2000; 5: 165-171.
76. Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. American Journal of Pathology 1997; 150: 815-821.
77. Veiga JP, Sallan SE, Nadler LM & Cardoso AA. Human acute lymphoblastic leukemia promotes angiogenesis in vivo: pre-clinical models to develop targeted intervention. Blood 2000; 96. 113a. abstract 484.
78. Vajkoczy P, Menger MD, Vollmar B et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel flk-I inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1: 31-41.
79. Fong TA, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-I/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Research 1999; 59: 99-106.
80. Thomas DA, Giles FJ, Cortes J et al. Antiangiogenic therapy in leukemia. Acta Haematologica 2001; 106: 190-207.
81. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947-4952.
82. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nature Medicine 1996; 2: 561-566.
83. Beran M, Cao, X, Estrov Z et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clinical Cancer Research 1998; 4: 1661-1672.
84. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 2001; 344. 1038-1042.
85. Ottmann OG, Druker BJ, Sawyers CL et al. A phase II study of imatinib mesylate (Glivec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
86. Thomas DA, Cortes J, Giles FJ et al. Combination of hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP). Blood 2001; 98: 803a. abstract 3340.
87. Hofmann WK, de Vos S, Elashoff D et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481-486.
88. Hofmann WK, Jones LC, Lemp NA et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
89. Uckun FM, Messinger Y, Chen CL et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clinical Cancer Research 1999; 5: 3906-3913.
90. Hale G, Swirsky D, Waldmann H et al. Reactivity of rat monoclonal antibody CAMPATH-I with human leukemia cells and its possible application for autologous bone marrow transplantation. British Journal of Haematology 1985; 60: 41-48.
91. Dyer MJ, Hale G, Hayhoe FGJ et al. Effects of Campath-IH antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-1439.
92. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine: results of a large international study. Blood 2000; 99: 3554-3561.
93. Maloney DG. Preclinical and phase I and II trials of rituximab. Seminars in Oncology 1999; 26: 74-78.
94. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998; 16: 2825-2833.
95. Ansell SM, Tschumper RC, Witzig TE et al. Chemokine upregulation in response to rituximab in B-cell non-Hodgkin's lymphoma. Blood 1999; 94: 86a. abstract 377.
96. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 1999; 17: 268-276.
97. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002; 346: 235-242.
98. Thomas DA, Cortes J, O'Brien SM et al. Significance of CD20 positivity in de novo acute lymphocytic leukemia (ALL). Blood 2000; 96: 109a. abstract 468.
99. Thomas DA, Cortes J, Giles FJ et al. Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood 2001; 98: 804a. abstract 3342.
100. Nadler LM, Anderson KC, Marti G et al. B4, a human B lymphocyte associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. Journal of Immunology 1983; 131: 244-250.
101. Grossbard ML, Lambert JM, Goldmacher VS et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology 1993; 11: 726-737.
102. Ek O, Gaynon P, Zeren T et al. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and I-asparaginase. Leukemia and Lymphoma 1998; 31: 143-149.
103. Herrera L, Farah RA, Pellegrini VA et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000; 14: 853-858.
104. Gunther R, Chelstrom LM, Finnegan D et al. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993; 7: 298-309.
105. Lew G, Gu L, Zhou M et al. BL22, an anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells from pediatric patients. Blood 2002; 100: 764a. abstract 3024.
106. Sievers EL, Appelbaum FA, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678-3684.
107. Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-1636.
108. Giles FJ, Kantarjian HM, Kornblau SM et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-413.
109. Leonard JP & Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (apolizumab). Seminars in Oncology 2002; 29: 81-86.
110. Shi JD, Bullock C, Hall WC et al. In vivo pharmacodynamic effects of HuID10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leukemia and Lymphoma 2002; 43: 1303-1312.
111. Link BK, Wang H, Byrd JC et al. Phase I trial of humanized ID10 (HUID10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proceedings of the American Society of Clinical Oncology 2000; 19: 24a. abstract 86
112. Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
113. Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.